McKesson Launches InspiroGene, a Dedicated Business to Guide and Support the Commercialization of Cell and Gene Therapies

IRVING, Texas--(BUSINESS WIRE)--Oct 1, 2024--

McKesson Corporation today announced the launch of InspiroGene™ by McKesson (“InspiroGene”), a dedicated business focused solely on supporting the commercialization of cell and gene therapies (CGTs). With a scalable, flexible suite of services and an experienced leadership team, InspiroGene enables manufacturers, payers, and providers to navigate the complex CGT commercialization landscape to ensure patients can access the life-changing treatments they need.

“Over the last few years, McKesson has leveraged its extensive supply chain expertise and customer-centric approach to build our cell and gene therapy business, with a focus on guiding innovative medicines from clinical development to commercial success,” said Joe DePinto, Head of Cell, Gene, and Advanced Therapies at McKesson. “Today’s launch of InspiroGene by McKesson is an exciting step forward in our evolution, with a new brand that reflects the work we are doing to transform care for patients and advance health outcomes for all.”

InspiroGene brings unparalleled experience in every stage of the CGT life cycle and has established the following solutions to address the complex challenges of bringing CGTs to market:

• Third-party logistics (3PL) programs that meet the unique demands of CGT manufacturers, with financial management solutions, logistics, and cutting-edge data analytics to provide seamless operations for CGTs.
• Specialty distribution services that leverage McKesson’s extensive supply chain network, offering high-touch logistics and advanced data analytics to ensure CGTs reach patients efficiently and effectively.
• Biologics specialty pharmacy solutions dedicated to CGTs, including precision dispensing to expedite time to treatment, and patient management services to efficiently address the unique needs of patients based on therapy type.
• CGT dedicated patient hub that provides tailored access and support services for patients, as well as operational case management for providers, patients, and caregivers.

In addition, InspiroGene offers a technology platform that provides visibility within the CGT value chain by integrating product data and financial flows to empower CGT manufacturers, providers, and patients to deliver exceptional care and achieve transformative clinical outcomes.

About InspiroGene by McKesson

InspiroGene by McKesson (“InspiroGene”) is a dedicated business focused solely on supporting the commercialization of cell and gene therapies (CGTs). At InspiroGene, we turn CGT innovation into a reality. We offer flexible, sustainable solutions to help manufacturers, payers, and providers navigate the complex CGT commercialization landscape. As an enduring ally, we’re dedicated to transforming patient care and driving better health outcomes. Learn more about the InspiroGene advantage at InspiroGene.com.

About McKesson Corporation

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.

View source version on businesswire.com:https://www.businesswire.com/news/home/20241001309245/en/

CONTACT: PR Contact

Lindsay Yanek

Communications

Lindsay.Yanek@McKesson.com

KEYWORD: TEXAS UNITED STATES NORTH AMERICA

Copyright Business Wire 2024.